Welcome to our dedicated page for Cassava Sciences news (Ticker: SAVA), a resource for investors and traders seeking the latest updates and insights on Cassava Sciences stock.
Cassava Sciences, Inc. (NASDAQ: SAVA) is a clinical-stage biotechnology company based in Austin, Texas that reports extensively on its efforts to develop simufilam, a proprietary, investigational oral small molecule for central nervous system (CNS) disorders. Recent news emphasizes a strategic shift toward tuberous sclerosis complex (TSC)-related epilepsy, following the discontinuation of its Alzheimer’s disease program after two Phase 3 trials did not meet their pre-specified endpoints.
News updates for SAVA commonly cover preclinical and clinical development milestones. Cassava has announced preclinical studies in mouse models of TSC-related epilepsy and focal cortical malformations, reporting that simufilam reduced seizure activity and alleviated neuronal abnormalities. The company also highlights presentations at scientific meetings, such as the TSC International Research Conference, where it shared data on seizure reduction and human safety findings from prior Alzheimer’s Phase 3 studies.
Regulatory and corporate developments are another key theme in Cassava’s news flow. Items include disclosures about the FDA placing the proposed proof-of-concept trial of simufilam in TSC-related epilepsy on full clinical hold pending additional data and protocol changes, as well as updates on the timing implications for clinical trial initiation. Investors also see announcements about leadership appointments in neuroscience and clinical development, board changes, participation in investor conferences, and financial results with commentary on cash resources and expense management.
Litigation and legal matters feature in Cassava’s news as well. The company has reported a binding term sheet to settle a consolidated securities class action for $31.25 million, subject to court approval, and has discussed related loss contingencies in its financial communications. For anyone tracking SAVA, this news page provides ongoing coverage of scientific publications, regulatory interactions, corporate governance changes, and financial and legal updates related to Cassava’s CNS drug development programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.